AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
ST. PETE BEACH, FLA. -- Maternal use of selective serotonin reuptake inhibitors during pregnancy may be associated with an increased risk of certain birth defects, Sura Alwan reported at the annual meeting of the Teratology Society.
Data obtained from a large, ongoing population-based, case-control study show women who used any SSRI between 1 month before and 3 months after conception had a significantly increased likelihood of having an infant with omphalocele, compared with those who reported no SSRI exposure during pregnancy (adjusted odds ratio, 3.3).
The risk was highest with paroxetine (adjusted odds ratio, 6.4), said Ms. Alwan, a Ph.D. student at the University of British Columbia, Vancouver.
Paroxetine accounted for 22% of all SSRI exposures in the study of 5,357 infants with major birth defects and 3,366 normal controls. Additionally, an association was found between any SSRI exposure and having an infant with tetralogy of Fallot (adjusted odds ratio, 6.3). No association was noted in SSRI use and other major classes of malformations studied. The data were derived from the National Birth Defects Prevention Study, a multisite study of birth defects risk factors, and were based on telephone interviews with the mothers, including data on infants delivered from 1997 to 2001.
Infants with recognized chromosomal anomalies or known syndromes were excluded from the study, which included adjustment for maternal BMI, age, and race. Adjustments for other confounding variables and effect modifiers--including maternal smoking, education, folic acid use, and gravidity--did not have a significant effect on the odds ratios, Ms. Alwan noted.
These findings expand the limited data on ...